Zolpidem, eszopiclone and zaleplon are non-benzodiazepine hypnotics acting at the GABA-A receptor, all Schedule IV controlled substances in the United States. They carry an FDA boxed warning added in 2019 for complex sleep behaviors including sleepwalking, sleep-driving and other activities while not fully awake, which have caused serious injuries and deaths, and they are contraindicated in anyone who has experienced such an episode. The FDA lowered recommended zolpidem doses for women in 2013 because of slower clearance and next-morning impairment. Fishtown Medicine prescribes controlled substances to members only, in Pennsylvania and New Jersey, with an in-person evaluation every six months and never as chronic maintenance.
TL;DR: Ambien, Lunesta and Sonata are the classic sleeping pills. They work, and they are controlled substances with an FDA boxed warning, which is the strongest warning the FDA issues. The warning is for complex sleep behaviors: people have driven, cooked, eaten and walked outside while not awake, and some have died. If that has ever happened to you on one of these, you must never take one again. Women were given lower recommended doses in 2013 because they clear zolpidem more slowly and were still impaired in the morning. These build tolerance, cause dependence, and produce rebound insomnia when stopped, so getting off them takes a plan. This practice prescribes them to members only, in PA and NJ, with an in-person visit every six months, and never as an indefinite nightly prescription. Tell Dr. Ash what is happening.
These are the drugs most people mean when they say sleeping pills, and they are the ones the whole online sleep category advertises that it does not prescribe.
They are not off the table here. They are handled differently, and the reasons are worth setting out.
What are the Z-drugs?
Three medications, named for the letter they share: zolpidem, sold as Ambien; eszopiclone, sold as Lunesta; and zaleplon, sold as Sonata.
They are non-benzodiazepine hypnotics that act at the same GABA-A receptor complex benzodiazepines do, with a preference for receptors containing the alpha-1 subunit. That selectivity is what was supposed to give them sedation without the anxiolytic, muscle-relaxant, and anticonvulsant effects of benzodiazepines, and to make them safer. In practice they turned out to share more of the benzodiazepine problems than the marketing suggested.
The practical difference between them is how long they last:
| Half-life | Best suited to | |
|---|---|---|
| Zaleplon (Sonata) | About 1 hour | Falling asleep, or a middle-of-the-night dose with hours left |
| Zolpidem (Ambien) | About 2.5 hours | Falling asleep, with an extended-release form for staying asleep |
| Eszopiclone (Lunesta) | About 6 hours | Staying asleep, with more next-morning residue |
What is the boxed warning?
In 2019 the FDA added a boxed warning, its most serious, for complex sleep behaviors on all three drugs.
Complex sleep behaviors means doing things while not fully awake and with no memory of them afterwards: sleepwalking, sleep-driving, preparing and eating food, making phone calls, and having sex. The agency reviewed 66 cases and found 20 deaths, from carbon monoxide poisoning, drowning, falls, hypothermia, fatal motor vehicle collisions, and apparent suicide, along with serious non-fatal injuries including burns, near-drownings, and self-harm.
Two things about the warning matter to a patient.
It can happen at recommended doses, and after a single dose. These were not all overdoses or long-term users.
A previous episode is now a contraindication. If you have ever done anything like this on one of these drugs, you should not take it again, and that includes the other two.
The risk is raised by alcohol, by other central nervous system depressants, and by taking a dose without leaving a full night for sleep.
Why do women take a lower dose?
Because they clear zolpidem more slowly, and the FDA acted on it in 2013.
Driving simulation and blood-level data showed that a meaningful proportion of women had enough zolpidem in their blood the next morning to impair driving. The FDA lowered the recommended starting dose for women to 5mg for immediate-release and 6.25mg for extended-release, half the previous figures, and recommended prescribers consider the lower dose for men as well.
This is one of the clearest examples in modern prescribing of a drug dosed for years without accounting for a difference that mattered. Anyone who was started on 10mg years ago and never had it revisited is worth reviewing.
Guidance from the Clinic
What are the other risks?
Next-morning impairment. Driving, reaction time, and memory can be affected the following day, particularly with eszopiclone and extended-release zolpidem.
Tolerance. The effect diminishes over weeks to months, which is why these were only ever studied and approved for short-term use.
Evidence-Based Treatment
Dr. Ash reviews the research - and applies it to your specific biology.
Dependence and rebound. Physical dependence develops with sustained use, and stopping produces rebound insomnia that is worse than the original problem for several nights. That rebound is the single biggest obstacle to getting off them, because it convinces people the drug was the only thing working.
Falls and fractures in older adults. The Z-drugs appear on the Beers Criteria as medications to avoid in adults 65 and over.
Anterograde amnesia, meaning no memory of the period after taking the dose.
Worsening of untreated sleep apnea, which is why the apnea question comes before the prescription, and which is covered on insomnia or sleep apnea.
Interaction with alcohol and opioids, both of which compound sedation and respiratory depression.
What do the guidelines say?
The American Academy of Sleep Medicine conditionally recommends zolpidem and eszopiclone for both sleep-onset and sleep-maintenance insomnia, and zaleplon for sleep-onset insomnia. Those are among the few positive recommendations in that guideline.
The American College of Physicians recommends CBT-I as first-line for all adults with chronic insomnia, with medication considered only after a shared decision when CBT-I alone has been insufficient.
Both of those are true at once, and together they describe the correct place for these drugs: effective, second in line, and time-limited.
How Fishtown Medicine prescribes them
To members only, in Pennsylvania and New Jersey, with an in-person evaluation every six months, and never as chronic maintenance.
That is a deliberately narrow door and the reasoning is the same as for every controlled substance here. A drug with dependence potential needs a prescriber who knows the patient's history, prescription monitoring checks, a standing follow-up rhythm, and a plan for when it should end. A single transaction supplies none of that.
One consequence matters and gets stated plainly: a membership lapsing while somebody is on one of these opens a taper or hand-off conversation and is never a reason for the prescription to stop silently, because abrupt discontinuation carries its own risk. The full policy is on controlled substances.
How do you get off one?
Slowly, with the sleep problem being treated at the same time.
A taper alone usually fails, for the reason above: rebound insomnia arrives, the nights are terrible, and the person restarts. What works better is combining a gradual dose reduction with CBT-I, so that something is replacing the drug as it comes down. Trials of that combination show better discontinuation rates than tapering alone.
Expect it to take months and not weeks, expect some difficult nights that are the rebound and not a relapse, and do it with a clinician instead of alone.
Key Takeaways
- Zolpidem, eszopiclone, and zaleplon are Schedule IV controlled substances that work and carry an FDA boxed warning.
- The warning covers complex sleep behaviors, which have caused deaths, can occur at recommended doses, and make a repeat prescription contraindicated after any episode.
- Women take lower zolpidem doses because they clear it more slowly, a change the FDA made in 2013.
- Tolerance, dependence, and rebound insomnia are the reason these were only ever meant for short-term use.
- Getting off one works far better when a taper is paired with CBT-I, and it takes months.
Related at Fishtown Medicine
- CBT-I for insomnia
- Is it insomnia or sleep apnea?
- Doxepin for sleep
- Trazodone for sleep
- Controlled substances policy
Scientific References
- US Food and Drug Administration. FDA adds Boxed Warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines. Drug Safety Communication, April 2019.
- US Food and Drug Administration. FDA Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem. January 2013.
- Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults. Journal of Clinical Sleep Medicine. 2017;13(2):307-349.
- Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Annals of Internal Medicine. 2016;165(2):125-133.
- Morin CM, Vallières A, Guay B, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia. JAMA. 2009;301(19):2005-2015.
- American Geriatrics Society. Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.
Frequently Asked Questions
Common Questions
Deep-Dive Questions
Ready when you are
The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.